The mRNA industry has expanded well beyond the COVID-19 vaccines that brought it to public attention. Moderna and BioNTech remain the largest players, but companies like CureVac, Arcturus Therapeutics, and several smaller firms are pushing the technology into cancer immunotherapy, gene editing, protein replacement for rare diseases, and even programmable cellular logic. Each company has staked out distinct technical ground, and the innovations separating them go deeper than which virus they are targeting next.
The Shared Foundation Everyone Builds On
Before looking at individual companies, it helps to understand two core technologies that nearly every mRNA company relies on in some form: chemically modified nucleosides and lipid nanoparticle delivery. When researchers first tried injecting synthetic mRNA into cells, the body’s immune sensors flagged it as foreign and destroyed much of it before it could do anything useful. The breakthrough that made modern mRNA therapeutics possible was swapping out one of the building blocks of the RNA strand, uridine, for a modified version called N1-methylpseudouridine. This modification suppresses activation of the immune sensors that would otherwise trigger inflammation and degrade the mRNA, allowing more of the injected material to be translated into protein.
The modification does double duty. It reduces inflammatory responses by limiting activation of the innate immune receptors that normally detect viral RNA, while simultaneously increasing the stability and protein output of the mRNA strand.1Meditory : The Journal of Medical Laboratory. PSEUDOURIDINE AND N1-METHYLPSEUDOURIDINE IN mRNA VACCINES MODULATE RETINOIC ACID INDUCIBLE GENE I (RIG-I) AND TOLL-LIKE RECEPTORS (TLR) ACTIVATION This was the chemistry behind the COVID-19 spike protein vaccines: the N1-methylpseudouridine modification improved the efficacy of the mRNA coding for the spike protein.2PubMed Central. Pseudouridine and N1-methylpseudouridine as potent nucleotide analogues for RNA therapy and vaccine development
Getting that mRNA into cells requires a vehicle, and the dominant one is the lipid nanoparticle. These are tiny fat-based capsules that protect the fragile mRNA in the bloodstream and then fuse with cell membranes to release their cargo inside. The key component is an ionizable lipid that responds to the acidic environment inside cellular compartments called endosomes, triggering the particle to break apart and release its mRNA payload into the cell’s interior where it can be read by the protein-making machinery.3PubMed Central. Time-Resolved Inspection of Ionizable Lipid-Facilitated Lipid Nanoparticle Disintegration and Cargo Release at an Early Endosomal Membrane Mimic Nearly every company in the mRNA space uses some version of this approach, though they differ in lipid formulations, and those differences have become a major source of both competitive advantage and patent disputes.
Moderna’s Broadening Ambitions
Moderna built the most commercially successful mRNA product to date with its COVID-19 vaccine, and the company is now leveraging that platform across respiratory viruses, oncology, and rare diseases. A significant focus is combination vaccines that protect against multiple respiratory viruses in a single shot. Rather than requiring separate injections for influenza, COVID-19, and respiratory syncytial virus (RSV), the goal is a single mRNA formulation encoding antigens from several pathogens at once.4PubMed Central. Respiratory virus mRNA vaccines: mRNA Design, clinical studies, and future challenges If successful, this would simplify annual vaccination schedules considerably, particularly for older adults who are at elevated risk from all three viruses.
Moderna’s platform advantage comes partly from its industrial-scale manufacturing infrastructure, built out during the pandemic, and partly from its deep investment in lipid nanoparticle chemistry. That chemistry, however, has not come without legal tangles. In early 2025, Moderna reached a $2.25 billion settlement with Genevant Sciences and Arbutus Biopharma to resolve long-running patent litigation over the lipid nanoparticle technology used in its vaccines.5Vaccine Insights. Industry Insights: mRNA milestones, industry restructuring, and regulatory upheavals in a turbulent month for vaccines The settlement underscores just how valuable the delivery side of the equation is: the lipid formulations that get mRNA into cells are as commercially important as the mRNA sequences themselves.
BioNTech and the Cancer Immunotherapy Frontier
BioNTech, Moderna’s fellow COVID vaccine maker, has been particularly aggressive in applying mRNA technology to cancer. The company’s most distinctive innovation is a concept called CARVac, which pairs two therapies: CAR-T cells (immune cells engineered to attack tumors) and an RNA vaccine that boosts those cells once they are inside the body. CAR-T therapy has been revolutionary for blood cancers, but solid tumors have been far harder to crack because the engineered immune cells tend to lose their potency over time.
BioNTech’s approach uses a nanoparticle-based RNA vaccine designed for body-wide delivery of the target antigen into immune-system tissues. In preclinical work, this promoted selective expansion of the CAR-T cells and led to regression of large tumors in mouse models, even when the initial dose of CAR-T cells was too low to work on its own.6PubMed. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors The idea is that the RNA vaccine acts like a periodic booster for the engineered immune cells, keeping them active and multiplying inside the patient.
In a phase 1 human trial targeting solid tumors expressing the protein CLDN6, early results suggested that the CARVac component might help boost CAR-T cell expansion, though researchers acknowledged that the overall impact was difficult to quantify given the small and highly variable patient group studied.7PubMed Central. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial The approach remains early-stage, but it represents a fundamentally different way of thinking about mRNA: not just as a one-time instruction set, but as a tool for controlling the behavior of living therapies already circulating in the body.
CureVac’s Bet on Unmodified mRNA
While Moderna and BioNTech built their platforms around chemically modified nucleosides, the German company CureVac has pursued a notably different path. CureVac’s core argument is that you can achieve the same goals, strong protein expression without triggering harmful immune responses, by carefully engineering the mRNA sequence itself rather than swapping in modified building blocks. Research from the company demonstrated that sequence-engineered, chemically unmodified mRNA could produce effective protein levels in large animals while avoiding activation of the innate immune system.8PubMed Central. Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals
The technique centers on codon optimization, rearranging the genetic code to use synonymous codons that the cell translates more efficiently, without changing the resulting protein. Studies have confirmed that codon-optimized mRNA sequences produce significantly higher protein levels in lab settings compared to unoptimized versions.9PubMed Central. Development and Evaluation of the Immunogenic Potential of an Unmodified Nucleoside mRNA Vaccine for Herpes Zoster CureVac’s COVID-19 vaccine candidate famously underperformed in late-stage trials compared to the modified-nucleoside vaccines from Moderna and BioNTech, which was a commercial setback. But the company has continued developing its platform for other applications, arguing that avoiding chemical modifications simplifies manufacturing and could offer advantages for certain therapeutic uses where you actually want some degree of immune activation.
Self-Amplifying RNA and the Low-Dose Promise
One of the most intriguing developments in the mRNA field is self-amplifying RNA, or saRNA. Companies like Arcturus Therapeutics have been at the forefront of this approach, which works on a simple but powerful principle: instead of delivering a fixed amount of mRNA that gets used up as cells read it, saRNA includes instructions for a viral replicase enzyme that copies the RNA inside the cell. The cell essentially becomes a small factory, amplifying the RNA message on its own.
The practical upshot is that you need far less starting material. Preclinical studies have shown that saRNA-based vaccines can produce immune responses comparable to conventional mRNA vaccines but at substantially lower doses.10PubMed Central. Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19 Lower doses mean lower manufacturing costs per dose, simpler logistics, and potentially fewer side effects. The self-amplification also promotes a type of immune response, involving type I interferons, that can enhance adaptive immunity beyond what a conventional mRNA vaccine provides.
Self-amplifying RNA platforms can generate strong immune responses, both antibody and cellular, with a single dose rather than the two-dose regimen that conventional mRNA vaccines typically require.11PubMed Central. Rise of the RNA machines – self-amplification in mRNA vaccine design Japan approved the first saRNA vaccine for COVID-19 in late 2024, making it the first regulatory approval for this class of technology. The long-term question is whether saRNA’s dose-sparing advantages will prove economically decisive enough to displace the conventional modified-mRNA approach that Moderna and BioNTech have already scaled to billions of doses.
Programmable mRNA and Cellular Logic
A smaller but fascinating corner of the mRNA world involves making mRNA “smart,” able to respond to conditions inside a cell before deciding whether to produce its protein. Researchers have built synthetic RNA-based logic circuits that function inside mammalian cells, creating AND, OR, and other logic gates that use microRNA levels and protein signals as inputs to control whether a therapeutic gene gets expressed.12Nature Communications. Synthetic RNA-based logic computation in mammalian cells
Why does this matter? Imagine an mRNA cancer therapy that only activates in cells expressing a specific combination of tumor markers, leaving healthy cells alone. Or an mRNA-based treatment that produces a missing protein only in the tissue where it is needed, based on the microRNA profile of that tissue. This is still largely preclinical work, and companies exploring it, like Strand Therapeutics (now acquired by Laronde), are at an earlier commercial stage than the vaccine makers. But the concept of programmable mRNA that makes decisions at the cellular level could eventually transform how targeted therapies are designed.
Delivering mRNA Beyond the Liver
A persistent limitation of lipid nanoparticle delivery has been that most formulations naturally accumulate in the liver. That is fine for vaccines, where the goal is just to produce antigen somewhere in the body, and it works well for liver-targeted therapies. But for mRNA treatments aimed at the lungs, spleen, brain, or other organs, liver accumulation is a problem. One of the most significant recent innovations in the delivery space is selective organ targeting, or SORT, a strategy for engineering lipid nanoparticles to deliver their cargo to specific non-liver tissues.
SORT works by adding a supplemental lipid molecule to the nanoparticle whose chemical structure determines where the particle ends up. By varying this molecule, researchers have designed nanoparticles that selectively target the lungs, spleen, or liver, and within those organs, specific cell types including epithelial cells, endothelial cells, B cells, T cells, and hepatocytes.13PubMed Central. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing The tissue specificity is determined by the chemical structure of the supplemental SORT molecule, giving researchers a tunable system rather than a one-size-fits-all delivery vehicle.14PubMed Central. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles
This technology is still being translated from academic labs into commercial products, but it could unlock a wide range of applications that are currently impractical, particularly in gene editing, where delivering CRISPR components to the right tissue is half the battle.
mRNA as a Vehicle for Gene Editing and Protein Replacement
Some of the most transformative potential for mRNA lies not in vaccines at all, but in using mRNA to deliver gene-editing tools or to replace missing proteins in patients with genetic diseases. The logic is straightforward: rather than permanently altering a patient’s DNA with a viral vector, you deliver mRNA encoding a CRISPR enzyme along with a guide RNA. The cell reads the mRNA, produces the editing enzyme, makes the targeted genetic change, and then the mRNA degrades. The edit is permanent, but the editing machinery is temporary, which reduces the risk of off-target effects that accumulate with long-lasting gene-editing tools.
In one demonstration, researchers used lipid nanoparticles to co-deliver Cas9 mRNA and a guide RNA targeting the Angptl3 gene in the liver of mice. The system achieved efficient gene knockdown, resulting in substantial reductions in the protein product of that gene as well as in LDL cholesterol and triglyceride levels.15PubMed Central. Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3 This points toward a future where mRNA-delivered CRISPR could treat conditions like high cholesterol, certain liver diseases, or inherited blood disorders with a single infusion rather than lifelong medication.
On the protein-replacement side, mRNA therapies have a theoretical advantage over traditional gene therapy: they can produce any missing protein without permanently integrating into the patient’s genome.16PubMed Central. Treating Cystic Fibrosis with mRNA and CRISPR One active area of development is cystic fibrosis, where the disease is caused by a defective or missing CFTR protein in the lungs. A lipid nanoparticle formulation called LUNAR-CFTR, carrying codon-optimized CFTR mRNA, was able to restore ion transport in cystic fibrosis airway cells to levels comparable to those achieved by the leading small-molecule drug combination, and a single dose improved mucus clearance by roughly threefold in a ferret model of the disease.17PubMed Central. LUNAR LNP delivery of CFTR mRNA restores channel function and improves mucociliary clearance in ferret cystic fibrosis airways This work is associated with Arcturus Therapeutics’ LUNAR lipid platform, illustrating how delivery innovation and therapeutic application intertwine.
Solving the Cold-Chain Problem
One of the earliest criticisms of mRNA vaccines was the punishing cold-chain requirement. The first COVID-19 mRNA vaccines had to be stored at extremely low temperatures, which made distribution in resource-limited settings extraordinarily difficult. A key innovation addressing this is lyophilization, essentially freeze-drying the lipid nanoparticle formulations into a stable powder that can be reconstituted before use.
Research has shown that lyophilized mRNA-LNP formulations retain their physical properties for at least 12 weeks at room temperature and at least 24 weeks when refrigerated at standard temperatures. In mouse studies, the lyophilized material maintained both its protein expression levels and its immunogenicity after months of storage, with no detectable decrease compared to freshly prepared material.18PubMed Central. Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine More recent work has focused on optimizing the lipid composition of these formulations specifically for post-lyophilization stability, with some formulations achieving high transfection efficiency not only in standard cell lines but also in retinal cells, hinting at potential applications for inherited eye diseases.19Regenerative Biomaterials. Development of lyophilized mRNA-LNPs with high stability and transfection efficiency in specific cells and tissues
If lyophilized mRNA products reach commercial scale, the implications for global health equity are substantial. The WHO’s mRNA Technology Transfer Programme, launched in 2021, aims to build local manufacturing capacity in low- and middle-income countries. A shelf-stable powder that can be shipped and stored without ultra-cold freezers would remove one of the biggest barriers to deploying mRNA vaccines in tropical climates and rural health systems.
Replicon-Based Cancer Vaccines and AI-Driven Antigen Selection
Beyond infectious disease, self-amplifying RNA technology is being applied to personalized cancer vaccines. The concept relies on neoantigen vaccines, treatments tailored to the unique mutations in an individual patient’s tumor. Since every tumor is genetically distinct, the challenge is identifying which mutated proteins will provoke the strongest immune response and then manufacturing a vaccine against those targets quickly enough to treat the patient.
Replicon-based platforms, which use the same self-amplifying approach described earlier, have shown the ability to generate both CD4+ and CD8+ T cell responses against tumor-specific neoantigens in animal models. When combined with immune checkpoint inhibitors or co-delivered with cytokine-encoding RNA, these responses were further enhanced. The approach has also demonstrated translatability in non-human primates, producing high-quality T cell responses that support clinical feasibility.20PubMed Central. Self-Replicating RNAs Drive Protective Anti-tumor T Cell Responses to Neoantigen Vaccine Targets in a Combinatorial Approach Companies like Gritstone Bio (now part of a broader oncology effort following its restructuring) have combined this type of replicon technology with machine-learning algorithms that predict which neoantigens are most likely to be presented on tumor cell surfaces, aiming to automate and speed up the antigen-selection step that is currently a bottleneck in personalized cancer vaccine development.
mRNA for Cellular Reprogramming
A less publicized but potentially transformative application of mRNA is in cellular reprogramming, the process of turning ordinary adult cells into induced pluripotent stem cells that can then become virtually any cell type. This is the foundation of regenerative medicine, with potential applications ranging from growing replacement tissues to creating patient-specific cells for drug testing. Among the various reprogramming techniques, mRNA-based methods are considered the most cleanly “footprint-free,” meaning they do not leave any permanent genetic material behind in the reprogrammed cells, and they tend to be the most efficient at producing stem cells suitable for clinical use.21PubMed Central. mRNA-Based Genetic Reprogramming
The advantage over DNA-based reprogramming methods is safety: because mRNA degrades after doing its job, there is no risk of the reprogramming genes integrating into the cell’s genome and potentially causing cancer or other problems down the line. Several companies and academic labs are exploring mRNA reprogramming as a route to producing clinical-grade stem cells at scale, though this work has not yet reached the commercial maturity of mRNA vaccines. The technology represents perhaps the furthest horizon of what mRNA therapeutics could become: not just delivering instructions for a single protein, but fundamentally rewriting what a cell is.